References
- Maceyka M and Spiegel S (2014) Sphingolipid metabolites in inflammatory disease. Nature 510, 58-67 https://doi.org/10.1038/nature13475
- Merrill AH Jr (2011) Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111, 6387-6422 https://doi.org/10.1021/cr2002917
- Hannun YA and Obeid LM (2018) Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol 19, 175-191 https://doi.org/10.1038/nrm.2017.107
- Nixon GF (2009) Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol 158, 982-993 https://doi.org/10.1111/j.1476-5381.2009.00281.x
- Chitnis T and Weiner HL (2017) CNS inflammation and neurodegeneration. J Clin Invest 127, 3577-3587 https://doi.org/10.1172/JCI90609
- Brambilla R (2019) Neuroinflammation, the thread connecting neurological disease : Cluster: "Neuroinflammatory mechanisms in neurodegenerative disorders". Acta Neuropathol 137, 689-691 https://doi.org/10.1007/s00401-019-02009-9
- Schwartz M and Baruch K (2014) The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J 33, 7-22 https://doi.org/10.1002/embj.201386609
- Norris GT and Kipnis J (2019) Immune cells and CNS physiology: Microglia and beyond. J Exp Med 216, 60-70 https://doi.org/10.1084/jem.20180199
- Arcuri C, Mecca C, Bianchi R, Giambanco I and Donato R (2017) The Pathophysiological Role of Microglia in Dynamic Surveillance, Phagocytosis and Structural Remodeling of the Developing CNS. Front Mol Neurosci 10, 191 https://doi.org/10.3389/fnmol.2017.00191
-
Zhu M, Wang X, Hjorth E et al (2016) Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase
$A{\beta}42$ Phagocytosis. Mol Neurobiol 53, 2733-2749 https://doi.org/10.1007/s12035-015-9544-0 - Kosicek M and Hecimovic S (2013) Phospholipids and Alzheimer's disease: alterations, mechanisms and potential biomarkers. Int J Mol Sci 14, 1310-1322 https://doi.org/10.3390/ijms14011310
- Assi E, Cazzato D, De Palma C, Perrotta C, Clementi E and Cervia D (2013) Sphingolipids and brain resident macrophages in neuroinflammation: an emerging aspect of nervous system pathology. Clin Dev Immunol 2013, 309302
- Liu Q and Zhang J (2014) Lipid metabolism in Alzheimer's disease. Neurosci Bull 30, 331-345 https://doi.org/10.1007/s12264-013-1410-3
- Yin F, Sancheti H, Patil I and Cadenas E (2016) Energy metabolism and inflammation in brain aging and Alzheimer's disease. Free Radic Biol Med 100, 108-122 https://doi.org/10.1016/j.freeradbiomed.2016.04.200
- Davies L, Fassbender K and Walter S (2013) Sphingolipids in neuroinflammation. Handb Exp Pharmacol 216, 421-430 https://doi.org/10.1007/978-3-7091-1511-4_21
- Mesa-Herrera F, Taoro-Gonzalez L, Valdes-Baizabal C, Diaz M and Marin R (2019) Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers. Int J Mol Sci 20, E3810
- Di Pardo A and Maglione V (2018) Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders. Front Neurosci 12, 249 https://doi.org/10.3389/fnins.2018.00249
- Szepesi Z, Manouchehrian O, Bachiller S and Deierborg T (2018) Bidirectional Microglia-Neuron Communication in Health and Disease. Front Cell Neurosci 12, 323 https://doi.org/10.3389/fncel.2018.00323
- Young MM, Kester M and Wang HG (2013) Sphingolipids: regulators of crosstalk between apoptosis and autophagy. J Lipid Res 54, 5-19 https://doi.org/10.1194/jlr.R031278
- Czubowicz K, Jesko H, Wencel P, Lukiw WJ and Strosznajder RP (2019) The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer's Disease and Other Neurodegenerative Disorders. Mol Neurobiol 56, 5436-5455 https://doi.org/10.1007/s12035-018-1448-3
- Jesko H, Stepien A, Lukiw WJ and Strosznajder RP (2019) The Cross-Talk Between Sphingolipids and Insulin-Like Growth Factor Signaling: Significance for Aging and Neurodegeneration. Mol Neurobiol 56, 3501-3521 https://doi.org/10.1007/s12035-018-1286-3
- Pahan K, Sheikh FG, Khan M, Namboodiri AM and Singh I (1998) Sphingomyelinase and ceramide stimulate the expression of inducible nitric-oxide synthase in rat primary astrocytes. J Biol Chem 273, 2591-2600 https://doi.org/10.1074/jbc.273.5.2591
- Liu L, Martin R and Chan C (2013) Palmitate-activated astrocytes via serine palmitoyltransferase increase BACE1 in primary neurons by sphingomyelinases. Neurobiol Aging 34, 540-550 https://doi.org/10.1016/j.neurobiolaging.2012.05.017
- de Wit NM, den Hoedt S, Martinez-Martinez P, Rozemuller AJ, Mulder MT and de Vries HE (2019) Astrocytic ceramide as possible indicator of neuroinflammation. J Neuroinflammation 16, 48 https://doi.org/10.1186/s12974-019-1436-1
- Jung JS, Shin KO, Lee YM et al (2013) Anti-inflammatory mechanism of exogenous C2 ceramide in lipopolysaccharide-stimulated microglia. Biochim Biophys Acta 1831, 1016-1026 https://doi.org/10.1016/j.bbalip.2013.01.020
- Fischer I, Alliod C, Martinier N, Newcombe J, Brana C and Pouly S (2011) Sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditions. PLoS One 6, e23905 https://doi.org/10.1371/journal.pone.0023905
- Grassi S, Mauri L, Prioni S et al (2019) Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases. Front Pharmacol 10, 807 https://doi.org/10.3389/fphar.2019.00807
- Karunakaran I and van Echten-Deckert G (2017) Sphingosine 1-phosphate - A double edged sword in the brain. Biochim Biophys Acta Biomembr 1859, 1573-1582 https://doi.org/10.1016/j.bbamem.2017.03.008
- Spiegel S and Milstien S (2011) The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 11, 403-415 https://doi.org/10.1038/nri2974
- Wu YP, Mizugishi K, Bektas M, Sandhoff R and Proia RL (2008) Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease. Hum Mol Genet 17, 2257-2264 https://doi.org/10.1093/hmg/ddn126
- Rothhammer V and Quintana FJ (2015) Control of autoimmune CNS inflammation by astrocytes. Semin Immunopathol 37, 625-638 https://doi.org/10.1007/s00281-015-0515-3
- Chalfant CE and Spiegel S (2005) Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J Cell Sci 118, 4605-4612 https://doi.org/10.1242/jcs.02637
- Lee JY, Han SH, Park MH et al (2018) Neuronal SphK1 acetylates COX2 and contributes to pathogenesis in a model of Alzheimer's Disease. Nat Commun 9, 1479 https://doi.org/10.1038/s41467-018-03674-2
- Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K and Marnett LJ (1998) Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 280, 1268-1270 https://doi.org/10.1126/science.280.5367.1268
- Muller N (2019) COX-2 Inhibitors, Aspirin, and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders. Front Psychiatry 10, 375 https://doi.org/10.3389/fpsyt.2019.00375
- Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-101 https://doi.org/10.1038/nature13479
- Buckley CD, Gilroy DW and Serhan CN (2014) Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40, 315-327 https://doi.org/10.1016/j.immuni.2014.02.009
- Fullerton JN, O'Brien AJ and Gilroy DW (2014) Lipid mediators in immune dysfunction after severe inflammation. Trends Immunol 35, 12-21 https://doi.org/10.1016/j.it.2013.10.008
- Mencarelli C and Martinez-Martinez P (2013) Ceramide function in the brain: when a slight tilt is enough. Cell Mol Life Sci 70, 181-203 https://doi.org/10.1007/s00018-012-1038-x
- Graham WV, Bonito-Oliva A and Sakmar TP (2017) Update on Alzheimer's Disease Therapy and Prevention Strategies. Annu Rev Med 68, 413-430 https://doi.org/10.1146/annurev-med-042915-103753
- Cerquera-Jaramillo MA, Nava-Mesa MO, Gonzalez-Reyes RE, Tellez-Conti C and de-la-Torre A (2018) Visual Features in Alzheimer's Disease: From Basic Mechanisms to Clinical Overview. Neural Plast 2018, 2941783 https://doi.org/10.1155/2018/2941783
- Heppner FL, Ransohoff RM and Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16, 358-372 https://doi.org/10.1038/nrn3880
- Visan I (2017) Alzheimer's disease microglia. Nat Immunol 18, 876
- Katsumoto A, Takeuchi H, Takahashi K and Tanaka F (2018) Microglia in Alzheimer's Disease: Risk Factors and Inflammation. Front Neurol 9, 978 https://doi.org/10.3389/fneur.2018.00978
-
Jazvinscak Jembrek M, Hof PR and Simic G (2015) Ceramides in Alzheimer's Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and
$A{\beta}$ Accumulation. Oxid Med Cell Longev 2015, 346783 https://doi.org/10.1155/2015/346783 - Couttas TA, Kain N, Daniels B et al (2014) Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. Acta Neuropathol Commun 2, 9 https://doi.org/10.1186/2051-5960-2-9
- Ceccom J, Loukh N, Lauwers-Cances V et al (2014) Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease. Acta Neuropathol Commun 2, 12 https://doi.org/10.1186/2051-5960-2-12
- Salter MW and Stevens B (2017) Microglia emerge as central players in brain disease. Nat Med 23, 1018-1027 https://doi.org/10.1038/nm.4397
- Ulland TK and Colonna M (2018) TREM2- a key player in microglial biology and Alzheimer disease. Nat Rev Neurol 14, 667-675 https://doi.org/10.1038/s41582-018-0072-1
- Fakhoury M (2018) Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy. Curr Neuropharmacol 16, 508-518 https://doi.org/10.2174/1570159X15666170720095240
- Kim SH, Noh MY, Kim HJ et al (2019) A Therapeutic Strategy for Alzheimer's Disease Focused on Immuneinflammatory Modulation. Dement Neurocogn Disord 18, 33-46 https://doi.org/10.12779/dnd.2019.18.2.33
- Alhouayek M and Muccioli GG (2014) COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends Pharmacol Sci 35, 284-292 https://doi.org/10.1016/j.tips.2014.03.001
- Bertolini A, Ottani A and Sandrini M (2002) Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem 9, 1033-1043 https://doi.org/10.2174/0929867024606650
- Chiang N and Serhan CN (2004) Aspirin triggers formation of anti-inflammatory mediators: New mechanism for an old drug. Discov Med 4, 470-475
- Kotilinek LA, Westerman MA, Wang Q et al (2008) Cyclooxygenase-2 inhibition improves amyloid-betamediated suppression of memory and synaptic plasticity. Brain 131, 651-664 https://doi.org/10.1093/brain/awn008
- Mitchell JA and Warner TD (2006) COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 5, 75-86 https://doi.org/10.1038/nrd1929
- Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M and Wu KK (1999) Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A 96, 5292-5297 https://doi.org/10.1073/pnas.96.9.5292
- Cuello AC (2017) Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum? Trends Pharmacol Sci 38, 956-966 https://doi.org/10.1016/j.tips.2017.07.005
- Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Primers 3, 17013 https://doi.org/10.1038/nrdp.2017.13
- Engelender S and Isacson O (2017) The Threshold Theory for Parkinson's Disease. Trends Neurosci 40, 4-14 https://doi.org/10.1016/j.tins.2016.10.008
- Charvin D, Medori R, Hauser RA and Rascol O (2018) Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov 17, 844 https://doi.org/10.1038/nrd.2018.184
- McGregor MM and Nelson AB (2019) Circuit Mechanisms of Parkinson's Disease. Neuron 101, 1042-1056 https://doi.org/10.1016/j.neuron.2019.03.004